loading . . . Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer Nature Reviews Clinical Oncology, Published online: 30 June 2026; doi:10.1038/s41571-026-01174-7Perioperative chemoimmunotherapy, comprising platinum-doublet chemotherapy plus an anti-PD-(L)1 antibody, has become the standard-of-care approach for patients with resectable non-small-cell lung cancer without an actionable driver alteration. However, the development of this approach has thus far been largely empirical, with limited capacity for adaptation of treatment strategies to better meet the needs of individual patients. In this Review, the authors discuss the potential for improvements in the current approach to perioperative therapy, including de-escalation for those with a pathological complete response, the capacity of various baseline and/or dynamic biomarkers to optimize outcomes, and the potential for escalation in patients with early evidence of a lack of responsiveness in the perioperative setting. http://dlvr.it/TTHhX2
